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At the time when treatment of small cell lung cancer (SCLC)
shows no immediate prospect of moving from a plateau
achieved more than a decade ago we must review all present-
ly available components of therapy and ensure their optimal
use. Cranial irradiation has been a part of treatment pro-
tocols in this disease for 20 years. Despite its widespread use
there are major differences between American, European and
British practice. It is interesting to speculate on the reasons
for this diversity and look for scientific justifications for the
often forcefully held opinions regarding its value.
SCLC behaviour resembles that of haematological malig-
nancies more than of any other common adult solid tumour.
Its chemo and radio sensitivity, widespread early dissemina-
tion and propensity for CNS spread made adoption of pro-
phylactic cranial irradiation (PCI) a logical treatment
development, based on experience in childhood acute
lymphoblastic leukaemia where introduction of PCI has lead
to near abolition of CNS relapse and significant improve-
ment in survival (Hustu et al., 1973).
The frequency of CNS involvement is directly proportional
to length of survival and can be estimated to be between 40
and 50% at 2 years (Komaki et al., 1983). This high fre-
quency of involvement is supported by autopsy data where
large numbers of patients are found to have clinically
unsuspected CNS disease (Osterlind, 1986). Symptomatic
manifestation of brain and spinal metastasis represents an
important type of failure in the prognostically favourable
group of patients.
The presently available data cannot predict individual
relapse risk for patients or unselected population groups. All
the known prognostic factors affecting probabilities of long
term survival such as performance status, stage and com-
pleteness of response to chemotherapy will play a role in
determining prospects of survival for a particular individual.
This population diversity may explain some of the variations
in reported frequency of CNS involvement in clinical practice
and will play an important part in the assessment of overall
benefit in clinical trials.
Majority of the nine published randomised trials confirm
that PCI in doses of about 30 Gy reduces significantly the
incidence of brain relapse (Jackson, 1985; Cox, 1978; Beiler,
1979; Maurer, 1980; Hansen, 1980; Eagan, 1981; Katsenis,
1982; Seydel, 1983). There is regrettably only one published
trial in patients with a complete response to chemotherapy
(Aroney, 1983). All the trials vary in the schedule and timing
ofcranial irradiation, patient selection and choice of systemic
therapy. All these factors can explain the lack of demonstr-
able survival effect in these individual studies or their over-
view.
The perceived benefit of a reduction in the number of CNS
replases was strengthened by reports of the poor symptom
relief and quality of life in patients treated for overt CNS
disease (Felletti, 1985; Lucas, 1986).
During this time reports of late neurotoxicity in long term
survivors started to appear in the literature (Catane, 1981).
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Some of the more extensively studied groups had up to half
of surviving patients suffering from ataxia, seizures and
variable deficits in higher mental functions, symptoms char-
acteristic of chronic leucoencephalophathy (Johnson, 1985).
Progressive radiological abnormalities could be demon-
strated in the majority of patients assessed by CT (Craig,
1984; Johnson, 1985; Lee, 1986; Laukkanen, 1988).
Whilst most of these patients received prophylactic cranial
irradiation, some had not. They were treated with a variety
of radiation schedules, diverse chemotherapy regimens and at
different times during their illness.
There are no prospective data or systematic assessment of
the frequency and degree of neurofunctional impairment in
patients with SCLC, its relationship to survival, frequency of
CNS relapse and the therapeutic strategy used.
The complex relationship between these parameters con-
sists of three main and somewhat interelated components.
The survival question
No individual randomised trial or collective data analysis has
shown any survival benefit for PCI treated patients. This fact
is often used as a strong argument against its use. The
individual trials are far too small to answer this question
convincingly and collective data analysis may be hampered
by the variety of prognostic factors which may have more
powerful effects on survival than any small survival advan-
tage attributable to PCI alone. Delay in CNS progression
may be an advantage even in the absence of survival benefit
for the majority of patients destined to die of systemic
relapse of their disease. Whether a threat of late morbidity
for a small number of long term survivors will outweigh the
significant early benefit for the majority of patients needs to
be tested. This will require a prospective randomised com-
parison with strict control of intervening variables and will
need a large number of patients. This will have to be a
multicentre endeavour. Individual experiences ofinvestigators
are selected and likely to bias the overall assessment. The
overall cost benefit analysis must include a quality of life
assessment, prospective neurofunctional and radiological test-
ing and a sufficiently long follow-up to allow for late mor-
bidity to manifest itself.
The radiation dose and fractionation schedule question
Most commonly used doses of 30-35 Gy in 10-15 daily
fractions were traditionally chosen to fit in with the prac-
ticalities of multimodality treatment protocols. This dose is
unlikely to sterilise permanently the CNS and increasing rate
of failure will be seen with increasing survival. It is known
that CNS radiation toxicity is highly dependent on radiation
fraction size (Sheline et al., 1980) and a fraction size of less
or equal to 1.8 Gy is chosen for irradiation of the CNS in the
case of brain tumours. The large fractions (>3.0 Gy) used in
the PCI schedules may have significantly contributed to the
CNS problems. The practical reluctance to adopt neuroonco-
logical fractionation schedules stems from the poor survival
of these patients and reservations about imposing a further
treatment-related burden on them. Twice daily fractionation
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could provide the answer by reducing the overall treatment
time and keeping the individual fraction size within the
tolerance restraint. This needs to be prospectively tested.
However, it may not be a practical use of limited resources.
The other strategy of reducing the radiation dose will lead to
increasing risk of early CNS relapse and is unlikely to be of
practical help in limiting late toxicity.
The timing of cranial irradiation
The temporal relationships between whole brain radiotherapy
and systemic chemotherapy and their critical interplay in
causation of leucoeacephalopathy has been graphically des-
cribed for intravenous methotrexate (Bleyer et al., 1980).
Experimental evidence of disruption of blood brain barrier
and radiation related endothelial disfunction exists from
recent in vitro studies (Vegt et al., 1985; Witte, 1989). That
alteration of drug accessibility could increase the neurotoxic
potential ofdrugs with well known CNS side-effects is under-
standable (Jellinger, 1983). Altered pharmacokinetics may
allow access to areas normally protected by blood brain
barrier and allow local radiosensitisation with drugs known
to have this potential (Neuwelt et al., 1984). Some clinical
support for these hypotheses comes from the literature where
the most severely disabled patients received intensive treat-
ment with nitrosoureas, Procarbazine, Methotrexate and
Adriamycin often concurrently and for long periods after
prophylactic cranial irradiation. This temporal potentiation
could also explain the low frequency of neurotoxicity in
studies employing PCI at the end of induction chemotherapy
or well separated in time from drug administration (Lishner
et al., 1990).
It is likely that respect for the parameters of CNS toler-
ance of fraction size and drug radiation interactions will
avoid some of the gross morbidity reported from earlier
studies.
The question of overall cost benefit assessment cannot be
answered without a prospective randomised trial taking
account of frequency and severity of neurological deficit and
quality of life in patients studied. It is ironic that at a time
when recent editorial by Turrisi (1990) calls for such a pro-
spective assessment the only trial attempting to answer the
late morbidity question (UKCCCR/MRC Study of PCI) is
failing due to lack of recruitment. At the same time a large
French collaborative trial which has adopted a simple design
addressing only survival question is thriving (Arriagada, per-
sonal communication).
Whilst the overall numbers of patients involved are small
the impact of CNS relapse or CNS toxicity is devastating for
each affected individual and their families. The minority of
patients with small cell lung cancer who have any prospect of
long term survival should benefit from our willingness to
review existing evidence and determine the value of PCI in
this disease once and for all.
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